The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy ...

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...